Which laboratory blood tests are indicated for the workup of memory loss?

Blood Work for Diagnosing Memory Loss

For any patient presenting with memory loss, obtain a comprehensive metabolic panel, complete blood count with differential, thyroid function tests (TSH), vitamin B12, homocysteine, calcium, magnesium, liver function tests, erythrocyte sedimentation rate, and C-reactive protein as first-line laboratory testing. 1

Core Laboratory Panel (First-Tier Testing)

The following blood tests should be obtained in virtually all patients with memory complaints to identify treatable metabolic causes and rule out systemic conditions that can mimic or exacerbate cognitive impairment:

Essential Tests

• Complete blood count (CBC) with differential - identifies anemia, infection, or hematologic disorders
• Complete metabolic panel including:
  • Sodium (hyponatremia can cause cognitive impairment)
  • Calcium (hypercalcemia from hyperparathyroidism)
  • Glucose (hypoglycemia, poorly controlled diabetes)
  • Liver function tests
  • Renal function (kidney disease affects cognition)
• Thyroid function tests (TSH) - hypothyroidism is a reversible cause
• Vitamin B12 level - deficiency causes cognitive decline
• Homocysteine - elevated levels associated with cognitive impairment
• Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) - screen for inflammatory conditions 1

Clinical Context

These laboratory abnormalities are found in 55-60% of patients with mild cognitive impairment or dementia, though only 1.5-3.5% have metabolic abnormalities that, when corrected, lead to clinical improvement 2. Importantly, 62.5% of these treatable abnormalities were previously unknown 2, making routine screening essential.

The most common abnormality is elevated cholesterol (found in 20-29% of patients), though this is less directly treatable for cognition 2. The key reversible causes identified by blood work include poorly controlled diabetes, renal failure, hyponatremia, folate or B12 deficiency, and hyperthyroidism 2.

Specialized Blood Biomarkers (Emerging Role)

Alzheimer's Disease-Specific Blood Biomarkers

Blood-based biomarkers for Alzheimer's disease should currently only be used in specialty care settings (memory clinics, neurology, geriatrics) after completing the basic laboratory workup and when AD pathology confirmation would change management. 3, 4

The validated blood biomarkers include:

• Phosphorylated tau-217 (p-tau217) - highest accuracy for AD diagnosis
• Phosphorylated tau-181 (p-tau181) - good diagnostic performance
• Amyloid-β 42/40 ratio - detects amyloid pathology
• Glial fibrillary acidic protein (GFAP) - marker of astrocytic activation
• Neurofilament light chain (NfL) - marker of neurodegeneration 3

Important Caveats for Blood Biomarkers

These tests are not yet ready for routine primary care use 3. They require:

• Specialized interpretation by dementia specialists
• Confirmation with CSF or amyloid PET when results are intermediate
• Understanding of pre-analytical factors (kidney disease, peripheral neuropathy can affect results)
• Recognition that no single inflammatory or neurodegenerative marker is sufficient - panels are needed 3

In specialty clinics, blood biomarkers show 68% of AD dementia patients have abnormalities in all four major biomarkers, and all have at least one abnormal marker 5. However, 50-79% of patients with subjective cognitive decline also show abnormalities, highlighting the need for expert interpretation 5.

Selective Additional Testing (When Clinically Indicated)

The following tests should not be routine but ordered based on specific clinical features 6:

• Rapid plasma reagin (RPR) or VDRL - if risk factors for syphilis
• HIV testing - if risk factors present
• Lyme antibody - if endemic area or exposure history
• Folate level - if dietary deficiency suspected
• Methylmalonic acid (MMA) - if B12 deficiency suspected but B12 level borderline
• Ammonia - if hepatic encephalopathy suspected
• HgbA1c - if diabetes control assessment needed
• Lipid profile - for cardiovascular risk assessment
• Antinuclear antibody (ANA), ANCA - if autoimmune condition suspected
• Paraneoplastic antibody panel - if rapidly progressive dementia 6

Critical Clinical Pitfalls

1. Don't skip basic labs even in "obvious" dementia - 62.5% of treatable causes are previously unknown 2

2. Don't order blood biomarkers for AD in primary care yet - insufficient validation in diverse primary care populations with multiple comorbidities 3

3. Don't rely on a single blood biomarker - panels are necessary to capture complex biology 3

4. Don't assume normal B12 rules out deficiency - consider MMA if clinical suspicion remains high

5. Recognize that blood biomarker abnormalities don't equal diagnosis - 50% of cognitively normal elderly may have abnormal AD biomarkers 5

Evidence Strength

The recommendation for basic laboratory testing is supported by multiple international guidelines from 2021-2025 1, 6, 1 with consistent recommendations across organizations. The evidence shows that while reversible dementia is rare (approximately 1%) 7, the basic blood panel is cost-effective and identifies treatable conditions that would otherwise be missed 8.

For blood-based AD biomarkers, the 2025 Alzheimer's Association guideline 4 and 2022 appropriate use recommendations 3 represent the most current expert consensus, emphasizing their role in specialty settings only, with ongoing research needed for broader implementation.